Showing 5631-5640 of 10820 results for "".
- CeraVe Launches Two Skin Care Productshttps://practicaldermatology.com/news/20140123-cerave_launches_two_skin_care_products/2459361/CeraVe has introduced the CeraVe Eye Repair Cream and CeraVe Intensive Stretch Marks Cream. The Eye Repair Cream combines three essential ceramides, to help repair and restore the delicate barrier around the eyes, with hydrating hyaluronic acid to help diminish fine lines and wrinkles. The Intensive
- Anti-Aging Technology Using the “Science of Heat” to be Presented at AACShttps://practicaldermatology.com/news/20140117-anti-aging_technology_using_the_science_of_heat_to_be_presented_at_aacs/2459368/An anti-aging technology that uses the “science of heat” will be presented tomorrow at the American Academy of Cosmetic Surgery (AACS) 30th Annual Scientific Meeting in Fort Lauderdale, FL. ThermiRF is a minimally invasive method of tightening sagging skin and reducing the appearance of fine lines a
- NYC's Eric Schweiger, MD Launches Book on Acne Treatmenthttps://practicaldermatology.com/news/20131230-nycs_eric_schweiger_md_launches_book_on_acne_treatment/2459384/New York City dermatologist Eric Schweiger, MD has launched his new book: 100 Acne Tips & Solutions: The Clear Clinic Guide to Perfect Skin, available December 2013 on
- Topical Nitric Oxide Shows Promisehttps://practicaldermatology.com/news/20131212-topical_nitric_oxide_shows_promise/2459395/Novan is kicking off a two-year program to support the pharmaceutical development of Nitric Oxide Advanced Healing (NOAH) technology, including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial-thickness and full-thickness thermal injuries. The
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- Strathspey Crown's Alphaeon Acquires Toxin Developer Evolus, Inc.https://practicaldermatology.com/news/20131004-strathspey_crowns_alphaeon_acquires_toxin_developer_evolus_inc/2459443/Strathspey Crown Holdings, LLC has acquired Evolus, Inc. of Santa Barbara, California for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, Alph
- TSLMS Announces New Name for its Meeting: Symposium for Cosmetic Advances and Laser Educationhttps://practicaldermatology.com/news/20131001-tslms_announces_new_name_for_its_meeting_symposium_for_cosmetic_advances_and_laser_education/2459447/The Tennessee Society for Laser Medicine & Surgery (TSLMS) announced that its 9th annual meeting Feb. 22-Mar. 2, 2014. The TSLMS introduced
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a
- Stelara Receives FDA Approval To Treat Active Psoriatic Arthritishttps://practicaldermatology.com/news/20130923-stelara_receives_fda_approval_to_treat_active_psoriatic_arthritis/2459457/The FDA recently approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. For the treatment of psoriatic arthritis, Stelara is administered as a 45